Market Research Report
Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020
|Published by||Global Markets Direct||Product code||361645|
|Published||Content info||55 Pages
Delivery time: 1-2 business days
|Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020|
|Published: April 30, 2020||Content info: 55 Pages||
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The latest report Type 2 Angiotensin II Receptor - Pipeline Review, H1 2020, outlays comprehensive information on the Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) - Angiotensin II receptor type 2 (AT2 receptor) is a protein encoded by the AGTR2 gene. AT2 receptor is highly expressed in the developing foetus, but its expression is very low in the cardiovascular system of the normal adult. Expression of the AT2 receptor can be modulated by pathological states associated with tissue remodeling or inflammation such as hypertension, atherosclerosis, and myocardial infarction. AT2 receptor plays an important role in vasodilatory role, and enhanced as a countervailing mechanism in cardiac hypertrophy, and in presence of vascular injury in hypertension and atherosclerosis.
The molecules developed by companies in Pre-Registration, Phase II, Preclinical and Discovery stages are 1, 3, 3 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Cardiovascular, Central Nervous System, Dermatology, Gastrointestinal, Respiratory, Genito Urinary System And Sex Hormones, Immunology, Infectious Disease, Metabolic Disorders, Musculoskeletal Disorders, Oncology and Women's Health which include indications Idiopathic Pulmonary Fibrosis, Atherosclerosis, Cardiomyopathy, Coronavirus Disease 2019 (COVID-19), Diabetic Neuropathic Pain, Fibrosis, Hyperlipidemia, Hypertension, Inflammatory Pain, Kidney Fibrosis, Liver Fibrosis, Myocardial Fibrosis, Non-Alcoholic Steatohepatitis (NASH), Polycystic Ovarian Syndrome, Postherpetic Neuralgia, Skin Inflammation, Systemic Sclerosis (Scleroderma) and Wounds.
Furthermore, this report also reviews key players involved in Type 2 Angiotensin II Receptor (Angiotensin II Type 2 Receptor or AGTR2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.